Prior studies evaluating the prognostic utility of cardiac CT angiography (CCTA) have been largely constrained to an all-cause mortality endpoint, with other cardiac endpoints generally not reported. To this end, we sought to determine the relationship of extent and severity of coronary artery disease (CAD) by CCTA to risk of incident major adverse cardiac events (MACEs) (defined as death, myocardial infarction, and late revascularization).
Introduction
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. 1, 2 The severity and prevalence of CAD increases with age, 3 with patients older than 75 years more likely having multivessel CAD. 4 However, the presence of CAD in young patients is not benign and is associated with significant morbidity and mortality. 5 Invasive coronary angiography (ICA) has traditionally been used as an anatomic standard for the diagnosis and prognosis of CAD. Coronary CT angiography (CCTA) of 64-detector rows or greater has emerged as a non-invasive modality that demonstrates high diagnostic performance compared with ICA. 6, 7 While CAD findings by CCTA have been examined for their prognostic utility in several prior investigations, published studies to date have been generally restricted to single centres and limited to measures of obstructive CAD and all-cause mortality endpoints. 8 -11 Further, given smaller sample sizes, these studies were constrained to evaluating cohorts in entirety and thus, were not able to discern differences in risk of major adverse cardiac events (MACEs), particularly based on differences in age. 5, 12 To this end, we sought to determine in a prospective international multisite registry of 15 187 patients the relationship of the extent and severity of CAD by CCTA to risk of incident MACEs and further, to examine this relationship as a function of age.
Methods

Study population
Study patients were identified from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry, a dynamic, international, multicentre, observational cohort study that prospectively collects clinical, procedural, and follow-up data on patients who underwent ≥64-detector row CCTA between 2005 and 2009 at 12 centres in 6 countries (Canada, Germany, Italy, Korea, Switzerland, and the USA). The rationale, design, site-specific patient characteristics, and follow-up durations have been described previously. 13 Patients undergoing CCTA at eight centres for whom the MACE follow-up were screened for the present study analysis, while those individuals with known CAD, as defined by prior myocardial infarction (MI) or coronary revascularization, or cardiac transplantations were excluded.
CCTA protocol and image reconstruction
CCTA scans were performed on a variety of different scanner platforms as previously described. 14 The scan parameters were as follows: 64 × 0.625/0.750-mm collimation, tube voltage 100 or 120 mV, effective 400-650 mA. Dose reduction strategies were utilized as previously described, 14 and the phase with the least amount of coronary artery motion was chosen for analysis. CCTAs were evaluated by an array of post-processing imaging techniques, and every arterial segment was scored in an intent-to-diagnose fashion.
Non-invasive coronary artery assessment by CCTA
The visual interpretation of CCTA at all the study sites was performed by level III equivalent cardiologist and all coronary segments were scored using a 16-segment coronary artery model. Coronary atherosclerotic lesions were graded by visual estimation using a 4-point grading system: none (0% luminal stenosis), mild (1 -49% luminal stenosis), moderate (50 -69% luminal stenosis), or severe (≥70% luminal stenosis). Per cent obstruction of the coronary artery lumen was based on a comparison of the luminal diameter of the segment exhibiting obstruction to the luminal diameter of the most normal-appearing site immediately proximal to the plaque. Plaque severity was graded on a per-patient, per-vessel, and persegment basis. Per-patient severity was defined by the maximal stenosis in any coronary segment at the ≥50% stenosis threshold, with a ≥50% stenosis left main considered obstructive. Per-vessel CAD severity was defined by the presence of a ≥50% stenosis in 0, 1, 2, or 3 coronary artery vessels.
Per-segment CAD severity was judged for individual coronary artery segments as we have previously described. 15 Briefly, a segment stenosis score was calculated as a measure of the overall coronary artery plaque burden, and was graded and summed for each coronary segment as none to severe plaque (0 -3) based on the extent of obstruction, with a total score ranging from 0 to 48. A segment involvement score was employed as a measure of overall coronary artery plaque distribution, and was calculated as the total number of coronary artery segments exhibiting plaque, irrespective of the degree of luminal stenosis within each segment (minimum ¼ 0; maximum ¼ 16). We further examined risk in association with any severe proximal stenosis in the left anterior descending, left circumflex, or right coronary vessels.
Clinical endpoints
The primary study endpoint was time to MACE, defined as death, MI and late revascularization (defined as .90 days after CCTA). Follow-up procedures were approved by all study centres' IRB. In the case of multiple event types, time to the earliest event constituted time to MACE. For the survival analyses, early revascularization was excluded and 507 MACE events were analysed. Increasing severity of CAD was associated with male gender, diabetes, hypertension, dyslipidaemia, family history of CAD, current smoking, typical angina and high pre-test likelihood of CAD (P ≤ 0.002 for all) ( Table 2 ). In univariable Cox proportional hazards models, increased hazards for MACE was associated with advanced age, male gender, diabetes, hypertension, untreated dyslipidaemia, current smoking, family history of CAD, and pre-test CAD likelihood ( Table 3) .
CAD findings for patients experience MACE vs. No MACE
Compared with patients who did not experienced an MACE event at follow-up, patients who did experience an MACE event had significantly more severe CAD in the majority of coronary segments ( Table 4) .
Per-patient, per-vessel and per-segment CAD severity and risk of MACE
In both univariable as well as multivariable Cox regression analysis considering age, and CAD risk factors, MACE was predicted by maximal per-patient non-obstructive and obstructive CAD ( Table 5 , Figure 1 ). By both univariable and multivariable Cox models, per-vessel obstructive CAD was related to a dose-response increased hazards for MACE for one-vessel, two-vessel, three-vessel, or LM CAD ( Table 5 , Figure 2 ). Similarly, in both univariable and multivariable Cox regression analysis, higher rates of incident MACE were associated with higher numbers of coronary segments with plaque, with stenosis-adjusted segments with plaque, with any severe proximal stenosis and with any plaque within the LM artery ( Table 5) . Sixty-two MACE events occurred in patients with no angiographic luminal narrowing by CCTA resulting in an annual event rate of 0.36% (Figure 1 ). On the other hand, 146 MACE events occurred in patients with non-obstructive CAD by CCTA resulting in an annual event rate of 1.22%, while there were 299 MACE events occurred in patients with obstructive CAD resulting in an annual event rate of 6.85%.
Age-stratified impact of CCTA-visualized CAD on MACE from all-causes Figure 3) . A dose-response relationship of MACE risk was observed per increasing decade of life ( Figure 4) . We also separately compared the individual components of MACE including death, MI, and late revascularization among patients ,65 and ≥65 years old ( Table 7) . All the individual components of MACE were higher for individuals ≥65 than ,65 years for normal, non-obstructive, one-, two-, and three-vessel or left main obstructive CAD than patients ,65 years ( Table 7) .
Age-stratified impact of early vs. late revascularization
We examined whether symptom-driven early revascularization (≤90 days) incidence differed by age, and noted differences among individuals ≥65 vs. ,65 years for typical angina (14.3 vs. 10.6%, P ¼ 0.035), atypical angina (8.8 vs. 3.4%, P , 0.001), non-cardiac pain (9.7 vs. 3.1%, P , 0.001), and shortness of breath (7.6 vs. 4.7%, P ¼ 0.001). When compared with individuals without CAD in patients with ,65 years, patients with ≥65 years experienced higher hazards for MACE for late revascularization [hazard ratio (HR) 11.67, 95% confidence interval (CI) 6.90-19.73, P ¼ 0.002], while patients ,65 years experienced higher hazards for MACE for late revascularization (HR: 17.73, 95% CI: 11.40-27.57, P ¼ 0.002).
Discussion
In this present study, we observed an independent prognostic value of both non-obstructive and obstructive CAD for future MACE on a per-patient, per-vessel and per-segment basis. We further observed the risk of future MACE based on CAD findings by CCTA as it related to age, and identified a heightened risk for future MACE for individuals ,65 vs. ≥65 years of age, even when adjusted for measures of CAD, when compared with their similar aged counterparts without evident CAD by CCTA. We further observed a dose-response relationship of MACE risk with each advancing decade of life. To our knowledge, the current study represents the first prospective large-scale multicentre international study to examine the incidence of MACE based on CCTA findings of CAD with adequate power (beta . its inability to reliably detect haemodynamically significant CAD. 22, 23 Future studies are likely required to further assess the haemodynamic significance of these obstructive lesions on CCTA.
A recent study of 24 775 stable patients from CONFIRM registry assessed the prognostic value CCTA for the prediction of all-cause mortality.
14 In this large, multicentre, multinational study, both non- Age-related risk of major adverse cardiac event risk obstructive (HR: 1.60, P ¼ 0.002) and obstructive CAD (HR: 2.60, P , 0.0001) were associated with increased all-cause mortality, with differences in multivariable risk-adjusted hazards for all-cause mortality noted for non-obstructive as well as increasing degrees of obstructive CAD. Importantly, the risk of 4-year death in this study was very low, indicating a 'warranty period' associated with a normal CCTA. As applied to MACE, Yiu et al. 24 assessed the prognostic significance of CCTA CAD findings for the prediction of MACE events in 2432 patients suspected of CAD. During 2.2-year followup, there were 59 (2.4%) MACE events, with significantly higher event rates noted in patients older than 60. The authors noted a dosedependent increase in MACE risk based on the presence of CAD regardless of age or gender, with patients without evidence of CAD on CCTA having very low event rates (≤0.3%). These findings in are accordance with a recent meta-analysis applied to acute symptoms for which 1559 adult patients with symptoms suggestive of ACS underwent CCTA and were assessed for MACE at a ≥30 days after their initial presentation. 25 This study demonstrated a ≥99% negative predictive valve of MACE based on the CCTA findings, suggesting the power of a normal CCTA to identify a low-risk population. The findings of these prior studies are in general agreement with the present study results and support the notion of a very low-risk state for patients with normal coronary arteries by CCTA; as well as an increasing risk of future MACE for both non-obstructive and obstructive CAD. However, the results of the present study directly and substantively extend these prior findings by stratifying risk according to age. When dichotomized by age ≥65 vs. ,65 years, patients ,65 years old had lower hazards of MACE for nonobstructive, one-, and two-vessel CAD, when compared with those who were ≥65 years old, they had similar hazard rates for three-vessel and LM disease. When stratified based on individual components of MACE, younger patients with three-vessel or LM disease had higher hazard rates for MI and late revascularization compared with individuals ≥65 years old. The potential explanations for these findings are manifold, and may relate to more aggressive forms of atherosclerosis in younger patients with a greater extent and severity of CAD when compared with their age-related counterparts. Future studies examining the phenomena that underscore this increased risk should now be pursued.
Even when stratified in a more granular fashion-that is, according to increasing decade of life-we observed a dose-response relationship of CAD extent and severity to MACE. This relationship was generally linear in nature, but increased for patients ≥80 years. Conversely, we noted a very low MACE event rate for patients with normal coronary arteries by CCTA, even among older patients. Importantly, we noted higher MACE rates in the very elderly population even among those with non-obstructive CAD by CCTA. When examined for components of MACE, mortality dominated as an endpoint in this population and thus, it is conceivable that these increased death rates may represent those of a non-cardiac nature. Future studies with cause-specific endpoints may be useful to further describe these findings.
Limitations
While this study addresses many of the shortcomings of prior smaller single-centre investigations evaluating the prognostic performance of Age-related risk of major adverse cardiac event risk CAD findings by CCTA for the prediction of MACE, it is nevertheless not immune to measures of selection, referral, and misclassification bias, as is the case for all observational studies. The information regarding the downstream treatment based on CCTA findings were also unknown, and it remains possible that changes in medical therapy following CCTA may have altered study outcomes. However, salutary treatment regimens would most likely mitigate rather than strengthen the current study's findings. Given the increasing risk associated with CAD findings by CCTA-specifically as it relates to age-future prospective studies examining differential treatment strategies may be useful to further expound upon these present study findings. Furthermore, stress testing data were not available in our study cohort, and future studies are likely required to assess the haemodynamic significance of obstructive lesions on CCTA.
Conclusion
In this large, prospective, multinational, multicentre CONFIRM registry, extent, and severity of CAD by CCTA is independent predictor of future cardiovascular events, with age-specific differences in risk. Importantly, normal coronary arteries by CCTA are associated with a low risk of future MACE, irrespective of age.
